ORBIMED ADVISORS LLC Insider Trading $KALA Kala Pharmaceuticals, Inc.
Get free email notifications about insider trading for ORBIMED ADVISORS LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of ORBIMED ADVISORS LLC. ORBIMED ADVISORS LLC is 10% Owner in CTI BIOPHARMA CORP ($CTIC) and Director in GLAUKOS Corp ($GKOS) and Director in RESPONSE BIOMEDICAL CORP ($RPBIF) and Director in INTERCEPT PHARMACEUTICALS INC ($ICPT) and in ACCELERON PHARMA INC ($XLRN) and Director in ProNAi Therapeutics Inc ($DNAI) and 10% Owner in AVEDRO INC ($AVDR) and 10% Owner in Relypsa Inc ($RLYP) and 10% Owner in Aerpio Pharmaceuticals, Inc. ($ARPO) and Director in Aerpio Pharmaceuticals, Inc. ($ZETAII) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and Director in SELECTA BIOSCIENCES INC ($SELB) and Director in SI-BONE, Inc. ($SIBN) and Director in Xtant Medical Holdings, Inc. ($XTNT) and 10% Owner in Roka BioScience, Inc. ($ROKA) and Director in Roka BioScience, Inc. ($ROKA) and 10% Owner in Kala Pharmaceuticals, Inc. ($KALA) and Director in Otonomy, Inc. ($OTIC) and 10% Owner in Arsanis, Inc. ($ASNS) and 10% Owner in Principia Biopharma Inc. ($PRNB) and Director in Acutus Medical, Inc. ($AFIB) and Director in SYNLOGIC, INC. ($MIRN) and 10% Owner in NeuroPace Inc ($NPCE) and 10% Owner in GRAYBUG VISION, INC. ($GRAY) and 10% Owner in Sientra, Inc. ($SIEN) and 10% Owner in TELA Bio, Inc. ($TELA) and Director in Loxo Oncology, Inc. ($LOXO) and 10% Owner in PIERIS PHARMACEUTICALS, INC. ($PIRS) and Director in PIERIS PHARMACEUTICALS, INC. ($PIRS) and Director in Dimension Therapeutics, Inc. ($DMTX) and 10% Owner in Guardant Health, Inc. ($GH) and 10% Owner in ViewRay, Inc. ($VRAY) and Director in ViewRay, Inc. ($VRAY) and Director in Turning Point Therapeutics, Inc. ($TPTX) and in Tricida, Inc. ($TCDA) and Director in Tricida, Inc. ($TCDA) and 10% Owner in Inspire Medical Systems, Inc. ($INSP) and Director in Inspire Medical Systems, Inc. ($INSP) and Director in Synthorx, Inc. ($THOR) and 10% Owner in scPharmaceuticals Inc. ($SCPH) and Director in Adaptimmune Therapeutics PLC ($ADAP) and Director in ALPINE IMMUNE SCIENCES, INC. ($NVLS) and Director in Corvus Pharmaceuticals, Inc. ($CRVS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and Director in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in Aeglea BioTherapeutics, Inc. ($AGLE) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and Director in Intellia Therapeutics, Inc. ($NTLA) and 10% Owner in Alector, Inc. ($ALEC) and Director in Alector, Inc. ($ALEC) and Director in Decibel Therapeutics, Inc. ($DBTX) and Director in NextCure, Inc. ($NXTC) and Director in LogicBio Therapeutics, Inc. ($LOGC) and Director in Silverback Therapeutics, Inc. ($SBTX) and Director in IMARA Inc. ($IMRA) and Director in Keros Therapeutics, Inc. ($KROS) and Director in Prelude Therapeutics Inc ($PRLD) and Director in PMV Pharmaceuticals, Inc. ($PMVP) and Director in ARMO BioSciences, Inc. ($ARMO) and Director in resTORbio, Inc. ($TORC) and Director in Prevail Therapeutics Inc. ($PRVL) and 10% Owner in SpringWorks Therapeutics, Inc. ($SWTX) and Director in Edgewise Therapeutics, Inc. ($EWTX) and Director in 89bio, Inc. ($ETNB) and Director in Arcutis Biotherapeutics, Inc. ($ARQT) and in Kinnate Biopharma Inc. ($KNTE) and Director in Oric Pharmaceuticals, Inc. ($ORIC) and Director in Repare Therapeutics Inc. ($RPTX) and Director in Fusion Pharmaceuticals Inc. ($FUSN) and Director in Terns Pharmaceuticals, Inc. ($TERN) and Director in Ikena Oncology, Inc. ($IKNA).
ORBIMED ADVISORS LLC in Kala Pharmaceuticals, Inc.
Trading Symbol: KALAIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of ORBIMED ADVISORS LLC: 10% Owner
Holdings: 3,422,840 shares
Latest Transaction: Feb 06 2018
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of ORBIMED ADVISORS LLC in Kala Pharmaceuticals, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ETNB, XLRN, AFIB, ADAP, TORC, AGLE, ARPO, ALEC, ALPN, ARQT, ARMO, BOLD, AVDR, CNST, CRVS, CTIC, DBTX, DMTX, EWTX, FUSN, GKOS, GRAY, GH, IKNA, IMRA, INSP, NTLA, ICPT, KALA, KROS, KNTE, LOGC, LOXO, NPCE, NXTC, ORIC, OTIC, PIRS, PMVP, PRLD, PRVL, PRNB, RLYP, RPTX, RPBIF, RYTM, SCPH, SELB, SIBN, SIEN, SRRA, SBTX, ROKA, SWTX, STDY, SYBX, THOR, TELA, TERN, TCDA, TPTX, VRAY, ASNS, XTNT
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 06 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.73 | 37,840 | 557,383 | 3,422,840 | 3.4 M to 3.4 M (+1.12 %) |
Feb 02 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.99 | 22,840 | 342,372 | 3,385,000 | 3.4 M to 3.4 M (+0.68 %) |
Feb 02 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 15.00 | 339,400 | 5,091,000 | 3,362,160 | 3 M to 3.4 M (+11.23 %) |
Jan 30 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.99 | 50,000 | 749,500 | 3,022,760 | 3 M to 3 M (+1.68 %) |
Jan 30 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.93 | 22,760 | 339,807 | 2,972,760 | 3 M to 3 M (+0.77 %) |
Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.91 | 64,637 | 963,738 | 2,950,000 | 2.9 M to 3 M (+2.24 %) |
Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.99 | 4,363 | 65,401 | 2,885,363 | 2.9 M to 2.9 M (+0.15 %) |
Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.98 | 75,000 | 1,123,500 | 2,881,000 | 2.8 M to 2.9 M (+2.67 %) |
Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.95 | 74,931 | 1,120,218 | 2,806,000 | 2.7 M to 2.8 M (+2.74 %) |
Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.50 | 38,354 | 556,133 | 2,731,069 | 2.7 M to 2.7 M (+1.42 %) |
Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.91 | 64,637 | 963,738 | 2,950,000 | 2.9 M to 3 M (+2.24 %) |
Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.99 | 4,363 | 65,401 | 2,885,363 | 2.9 M to 2.9 M (+0.15 %) |
Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.98 | 75,000 | 1,123,500 | 2,881,000 | 2.8 M to 2.9 M (+2.67 %) |
Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.95 | 74,931 | 1,120,218 | 2,806,000 | 2.7 M to 2.8 M (+2.74 %) |
Jan 24 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 14.50 | 38,354 | 556,133 | 2,731,069 | 2.7 M to 2.7 M (+1.42 %) |
Jan 12 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 15.40 | 28,446 | 438,068 | 2,692,715 | 2.7 M to 2.7 M (+1.07 %) |
Jan 12 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 13.65 | 41,700 | 569,205 | 2,664,269 | 2.6 M to 2.7 M (+1.59 %) |
Jan 12 2018 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 12.83 | 170,338 | 2,185,437 | 2,622,569 | 2.5 M to 2.6 M (+6.95 %) |
Jul 27 2017 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 10,707,985 | 0 | 0 | |
Jul 27 2017 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 15.00 | 319,333 | 4,789,995 | 2,375,279 | 2.1 M to 2.4 M (+15.53 %) |
Jul 27 2017 | KALA | Kala Pharmaceutica ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 2,055,946 | 0 | 2,055,946 | 0 to 2.1 M |
Page: 1